REGENXBIO Inc. (NASDAQ:RGNX) Receives $34.82 Consensus Price Target from Brokerages

REGENXBIO Inc. (NASDAQ:RGNX) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $34.82.

RGNX has been the subject of several recent analyst reports. StockNews.com lowered REGENXBIO from a “hold” rating to a “sell” rating in a research report on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and set a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Chardan Capital reiterated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Wednesday, November 20th. Raymond James reissued an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research note on Thursday, October 10th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of REGENXBIO in a report on Wednesday, January 15th.

Institutional Trading of REGENXBIO

Hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in shares of REGENXBIO by 141.3% in the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after buying an additional 67,948 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after acquiring an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in REGENXBIO by 602.9% in the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 17,533 shares in the last quarter. Squarepoint Ops LLC grew its holdings in REGENXBIO by 630.9% in the second quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock worth $1,711,000 after purchasing an additional 126,249 shares during the last quarter. Finally, FMR LLC increased its position in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Trading Up 2.2 %

Shares of RGNX opened at $8.07 on Friday. REGENXBIO has a twelve month low of $6.56 and a twelve month high of $28.80. The company’s fifty day simple moving average is $8.23 and its 200-day simple moving average is $10.19. The company has a market cap of $399.83 million, a P/E ratio of -1.60 and a beta of 1.28.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.